Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management
Clinical and Molecular Hepatology · 2026
DOI: 10.3350/cmh.2025.0857 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Harendran Elangovan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, Westmead, NSW, Australia. Hauptthemen laut MEDLINE: Incretins, Metabolic Diseases, Kidney Diseases, Liver Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Sydney, National Health and Medical Research Council, MRFF.
Abstract (Originalsprache)
Steatotic liver disease (SLD) is a leading cause of disease globally and demands new therapeutic approaches to mitigate underlying metabolic dysregulation. Incretin-based therapies are emerging as a viable prospect to fulfil this unmet niche. A literature review to inform the evidence base for incretin focussed pharmacology in the metabolic liver diseases space and an informed commentary on unmet areas of need. Incretin-based therapeutics demonstrate multifarious benefits across the chronic metabolic disease spectrum with promising data across the continuum of pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, Westmead, NSW, Australia.
- MASLD Research Center, University of California San Diego, San Diego, CA, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore.
- Saarland University Medical Center, University of the Saarland, Homburg, Germany and PharmaScienceHub (PSH), Saarbrücken, Germany.
- MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Division of Gastroenterology and Hepatology, Houston Methodist Hospital, Houston, TX, USA.
Förderung
- University of Sydney
- National Health and Medical Research Council
- MRFF
- Cancer Institute, NSW
- Boston Scientific Corporation
- Olympus Medical
- Roche and Astellas
- Ansh Inc
Zitieren
APA
Elangovan, H., Loomba, R., Muthiah, M., Schattenberg, J., Zheng, M. H., Noureddin, M., Mantzoros, C., & George, J. (2026). Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.0857
Vancouver
Elangovan H, Loomba R, Muthiah M, Schattenberg J, Zheng MH, Noureddin M, et al. Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2025.0857
BibTeX
@article{Elangovan2026,
author = {Elangovan, Harendran and Loomba, Rohit and Muthiah, Mark and Schattenberg, Jörn and Zheng, Ming Hua and Noureddin, Mazen and Mantzoros, Christos and George, Jacob},
title = {Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2025.0857}
}
EUVIMED